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SUMMARY 
Among the studies of systemic hormonal and physiological abnormalities associated with anxiety 
disorders, the most consistent and extensive findings suggest (a) peripheral adrenergic hyperactivity 
(including increases in norepinephrine but not epinephrine) and functional dysregulation, 
(b) increased incidence of mitral valve prolapse in panic patients, and (c) normal suppressibility of 
the hypothalamic-pituitary-adrenal cortical endocrine system with dexamethasone in panic patients. 
Other less-certain findings include (a) increased circulating concentrations of plasma ACTH and/or 
cortisol, and prolactin, in panic patients, (b) increased platelet monoamine oxidase activity in 
generalized anxiety and/or panic patients, (c) decreased gonadal axis activity in some anxious 
individuals, (d) decreased nighttime melatonin plasma concentrations in panic patients, and 
(e) peripheral a2 and B-adrenoreceptor down-regulation, with normal semtonin binding parameters. 
These findings, taken together, provide tentative support for dysfunction in adrenergic and 
GABAergic central nervous system mechanisms in people with anxiety disorders. Abnormal 
anxiety and normal stress both show evidence of adrenergic hyperactivity; however, there appear to 
be differences in hormonal pmtiles, especially the apparent lack of increase of epinephrine during 
panic attacks, as well as differences in the reactivity of the system, and in the "trigger" mechanisms 
which determine when the response occurs. 
INTRODUCTION 
RECENT ADVANCES in diagnosis and treatment have led to a renewal of  interest in the 
pathophysiology of anxiety symptoms and anxiety disorders. Because the central nervous system 
is relatively inaccessible to study in humans, most research has been either with animal models of 
anxiety or with presumptive peripheral psychobiological markers; it is usually assumed that 
peripheral changes provide "downstream" or "final common path" indicators of central nervous 
system activity. Human studies have typically involved one of two paradigms: study of 
peripheral changes occurring in normal individuals under stressful "anxiety"-provoking 
circumstances (natural or experimentally induced), or study of differences between normals and 
individuals with anxiety disorders. Although it is often assumed, at least implicitly, that by 
studying one paradigm, knowledge is also gained about the other, there is little empirical support 
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TABLE I. ENDOCRINE FUNCTIONING IN ANXIETY DISORDERS 
Stress in Genera l i zed  O t h e r  
Hormone Normals Panic/Agoraphobia Anxiety Disorder Phobias Groups 
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for this point of view. Thus, the large body of research on the psychobiology of stress (e.g., Van 
Toiler, 1979; Rose, 1980) might be about mechanisms totally different from those which are 
associated with anxiety disorders. In order to understand the pathophysiology of abnormal 
anxiety, individuals with these disorders must be studied specifically. 
The purpose of this article is to review studies of the psychobiological characteristics of 
individuals with anxiety disorders. Most of the studies have focused on endocrine and/or 
autonomic nervous system changes; these will be reviewed separately, including studies of 
peripheral receptor status. Following the review, the results will be integrated in an attempt to 
indicate what these studies tell about the pathophysiology of abnormal anxiety. Finally, 
strategies and new directions will be suggested, to further understand the pathophysiology, and 
ultimately the etiology, of pathological anxiety states. 
Many of the studies described below did not use formalized diagnostic criteria to define the 
patient population under study. Studies in which diagnostic criteria are not explicitly specified 
typically appear to involve patients with panic attacks (with or without agoraphobia) and/or 
generalized anxiety disorder, as defined by DSM-E[I (American Psychiatric Association, 1980) 
or DSM-III-R (American Psychiatric Association, 1987). Patients designated as 
"neurocirculatory asthenia" or related terms may or may not represent the same patients; the 
pathophysiology of these patients have also been studied (e.g., Mantysaari, 1984). 
Psychoendocr ine  F ind ings  
Patients with anxiety disorders show differences in the circulating concentrations of several 
hormones in comparison to normal subjects. These include catecholamines and MHPG, 
cortisol and ACTH, growth hormone, prolactin, thyroid axis hormones, gonadal axis hormones, 
glucose regulatory hormones, melatonin, and B-endorphin. The endocrine abnormalities are 
summarized in Table I. 
Catecholamine concentrations studied in anxious people include epinephrine, 
norepinephrine, dopamine, and catecholamine metabolites, especially 3-methoxy-4-hydroxy- 
phenethyleneglycol (MHPG). Norepinephrine is of interest as a marker of systemic adrenergic 
activity, while epinephrine is usually considered to be released as part of a "stress" reaction. 
Catecholamine metabolites are indicators of both peripheral and central (especially MHPG) 
nervous system adrenergic activity. 
Stress or anxiety in normal subjects usually produces elevations of circulating 
catecholamines (Frankenhaeuser, 1971; Ursin et al., 1978; Van Toller, 1979; Rose, 1980; 
Lader, 1982; Axelrod & Reisine, 1984). Catecholamine elevations have also been observed in 
patients with mixed anxiety and depression (Wyatt et  al., 1971), specific phobias (Chosy et al., 
1970; Nesse et  al., 1985a), and generalized anxiety (Mathew et  al., 1980a; 1980c; 1981a). 
MHPG appears to be positively correlated with anxiety levels in normal subjects and 
psychiatric patients, including high trait-anxious individuals, although the actual levels may not 
be significantly elevated (Uhde et  al., 1982; Potter et al., 1983; Davis et  al., 1985). People with 
high ratings of trait anxiety have a higher plasma MHPG response to pain and a greater heart 
rate response to intramuscular epinephrine than low trait-anxiety individuals (Mathew et  al., 
1980c; Uhde et  al., 1982). In another study, high trait anxious people did not have an elevation 
of resting plasma epinephrine or norepinephrine; however, moderate exercise did lead to an 
exaggerated norepinephrine rise (Peronnet et  al., 1986). 
Basal plasma epinephrine, norepinephrine, MHPG and possibly dopamine may be elevated 
in panic disorder patients compared to normal subjects (Ballenger et  al., 1984; Cameron et al., 
1984; Nesse et  al., 1984; Villacres et  al., 1987), although we found normal basal supine and 
posturally stimulated concentrations (unpublished data), another study reported pre-lactate 
MHPG concentration to be normal (Pohl e t  a l . ,  1987), and a third study reported 
norepinephrine levels and kinetics to be normal (Villacres et  al., 1987). In ambulatory patients, 
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urinary norepinephrine, but not epinephrine, is also significantly elevated (Nesse et al., 1985b), 
but urinary MHPG may be decreased, normal, or increased (Hamlin et al., 1983; Sheehan e t  
al.,  1983a; Roy-Byrne et al. ,  1986a). Challenge testing has yielded conflicting results 
concerning epinephrine and norepinephrine changes associated with lactate infusions (Appleby 
et al., 1981; Liebowitz et al., 1985; Cart et al., 1986); increases ranged from moderate to non- 
existent. MHPG was minimally responsive to lactate infusions (Carr et al., 1986; Pohl et al., 
1987), and isoproterenol infusion (Pohl et al., 1987). Challenge testing with yohimbine, an ~ -  
adrenergic receptor antagonist, demonstrated increases in MHPG in both patients and normals, 
with more severe panic patients showing the largest increases (Charney et al. ,  1983; 1984; 
Charney & Heninger, 1985a; 1985b); clonidine, an ix2 agonist, produced greater MHPG 
decreases in patients than normals (Chamey & Heninger, 1986a). Caffeine-induced increases 
in anxiety did not raise MHPG (Uhde et al., 1984a; Chamey et al., 1985), while situationally 
produced anxiety in panic patients did produce increases in MHPG in one study (Ko et al., 
1983), but not in another (Woods et al., 1987). Norepinephrine and MHPG were minimally 
changed during "spontaneous" (unexpected) panic attacks, and epinephrine showed no change 
at all (Cameron et al., 1987); it was suggested that posture and activity levels might play a role 
in hormonal (and physiological) reactivity in these patients. In summary, catecholamines and 
catecholamine metabolites are frequently elevated in patients with anxiety disorders; however, 
elevations have not always been observed and are clearly not a sine qua non for anxiety 
symptoms. 
Cortisol in humans is released from the adrenal cortex in response to ACTH. 
Corticosteroids are elevated under stressful conditions in normal subjects (Mason et al., 1965; 
Ursin et al., 1978; Van Toiler, 1979; Rose, 1980; Axelrod & Reisine, 1984). In patients with 
simple phobias, plasma cortisol elevations are associated with acute phobic anxiety in some 
circumstances but not in others (Curtis et al., 1976; 1978; Fredrikson et al., 1985; Nesse et al., 
1985a). In patients with generalized anxiety urinary corticosteroid excretion has been reported 
as both normal and elevated (Persky et al., 1956; Rosenbaum et al., 1983); also, there is one 
report of an increased incidence of abnormal dexamethasone suppression tests (DST) 
(Schweizer et al., 1986a). Patients with obsessive-compulsive disorders are also reported to 
have an increased incidence of positive DST's (Cameron et al., 1986a; Zohar & Insel, 1987). 
In patients with panic disorder, resting plasma cortisol concentrations are normal or mildly 
elevated (Nesse et al., 1984; Villacres et al., 1987; Holsboer et al., in press), and the incidence 
of abnormal dexamethasone suppression tests is normal or only slightly increased (Curtis et al., 
1982; Lieberman et al., 1983; Sheehan et al., 1983b; Avery et al., 1985; Peterson et al., 1985; 
Roy-Byrne & Uhde, 1985; Bridges et al., 1986). Studies of panic patients have reported both 
normal and elevated basal cortisol and ACTH concentrations as well as reduced cortisol and 
ACTH responses to CRH (corticotropin releasing hormone) (Roy-Byme & Uhde, 1985; Roy- 
Byme et al., 1985; 1986b; Holsboer et al., in press). Cortisol changes were inconsistent during 
"spontaneous" panic attacks, although cortisol elevations appeared to be correlated with attack 
severity (Cameron et al., 1987). Similar to the reports on catecholamines, there are conflicting 
data on whether lactate-induced panic is associated with cortisol elevations (Appleby et al., 
1981; Liebowitz et al., 1985, Carr et  al., 1986). Cortisol was elevated in caffeine-induced 
anxiety in normal subjects (Uhde et  al., 1984a; Charney et  al., 1985) and panic patients 
(Chamey et al., 1985), but cortisol during situational panic attacks was normal (Woods et al., 
1987). Cortisol was also increased more in yohimbine-induced panic than in normals (Chamey 
et al., 1987). Finally, the cortisol response to the mirror-drawing test was reported to be greater 
in "neurotic" (anxious?) subjects than in normals (Miyabo et al., 1976). Thus, there is some 
evidence of increased hypothalamic pituitary-adrenal cortical (HPA) activity under some 
circumstances in anxiety disorders; nevertheless, in panic patients, the axis appears to be 
normally suppressible, as indicated by the DST results. 
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Other hormones, including growth hormone, prolactin, thyroid, and gonadal hormones are 
also systemic indicators of hypothalamic-pituitary function. The various hormones are 
regulated by different releasing factors and different combinations of neurotransmitter inputs at 
the hypothalamic level. Growth hormone is responsive to stress, although not as strongly or 
reliably as catecholamines or cortisol (Ursin et al., 1978; Van Toiler, 1979; Rose, 1980). 
Plasma growth hormone increases also occur in some phobics during in vivo exposure (Curtis 
et al., 1979; Nesse et  al., 1985a). Resting growth hormone may be elevated in panic patients 
(Nesse et  al., 1984; Uhde et al., 1985), and the growth hormone response to clonidine challenge 
appears to be blunted (Uhde et al., 1985; 1986; Chamey & Heninger, 1986a). Growth hormone 
response to lactate was reported to be similar in panic patients and normals (Carr et al., 1986). 
Growth hormone may be decreased during situational panic attacks (Woods et al., 1987). And, 
like cortisol, growth hormone was reported to be more responsive to the mirror-drawing test in 
"neurotic" patients (Miyabo et al., 1976). Growth hormone responses to "spontaneous" panic 
attacks showed substantial inter-subject differences (Cameron et al., 1987). 
Circulating prolactin concentrations are sometimes elevated in association with stress 
(Rose, 1980), but do not change in association with phobic anxiety (Nesse et al., 1980), 
relaxation treatment of generalized anxiety (Mathew et al., 1979), or the cold pressor test in 
panic patients (Grunhaus et  al., 1983). Prolactin increases have been observed at rest in panic 
patients and in response to lactate-induced panic in two studies (Appleby et  al., 1981; 
Liebowitz et  al., 1985), but not in a third (Carr et  al., 1986). Prolactin responses to the 
serotonin precursor tryptophan were normal in panic patients (Chamey & Heninger, 1986b); 
hormonal responses (cortisol, growth hormone, prolactin) to MCPP, a serotonin agonist, also 
indicated normal serotonin activity in panic patients (Charney et al., 1987b). A prolactin 
increase occurred during "spontaneous" panic attacks (Cameron et al., 1987), but prolactin may 
be decreased during situational attacks (Woods et al., 1987). 
Thyroid function changes are implicated in stress (McKenzie, 1974), including the 
similarity between thyrotoxic and somatic anxiety symptoms (Lader, 1981), the increased 
incidence of thyroid dysfunction in phobias of various kinds (Lindemann et al., 1984), the 
possible association between hyperthyroidism and panic attacks (Katerndahl & Vande Creek, 
1983) and generalized anxiety (Kathol et al., 1986), and blunted TSH (and prolactin) responses 
to TRH (thyrotropin releasing hormone) in panic patients (Roy-Byrne & Uhde, 1985; Roy- 
Byme et al., 1985). Plasma TSH levels did not change during phobic anxiety (Nesse et al., 
1982). An increased frequency of thyroid hormone abnormalities was reported in women with 
panic attacks (Matuzas et  al., 1987). 
Unlike the increases seen in several other hormones, circulating testosterone concentrations 
sometimes fall in response to stress (Ursin et al., 1978; Curtis, 1979; Rose, 1980), and also 
during lactate-induced panic (Appleby et al., 1981). However, LH and FSH changes in 
response to stress generally have not been observed (Ursin et al., 1978; Roso, 1980), including 
no response to lactate in panic patients (Carr et al., 1986). Sex hormone fluctuations in women 
during the menstrual cycle may be related to changes in anxiety levels, although fluctuations 
have not always been observed (Golub, 1976; Abplanalp et al., 1977; Lahmeyer et al., 1982; 
Rubinow & Roy-Byrne, 1984; Veith et al., 1984, Chamey & Heninger, 1986a; Cameron et al., 
in press). Finally, pregnancy, possibly mediated by the associated endocrine changes, is 
associated with an improvement in panic anxiety (George et al., 1987). 
To summarize the relationship between anxiety and the circulating concentrations of those 
pituitary hormones which have been studied: (a) ACTH and/or cortisol may be elevated in 
panic or generalized anxiety patients; (b) growth hormone shows an inconsistent pattern; 
(c) prolactin elevations may be specifically associated with panic anxiety; (d) thyroid axis 
abnormalities are probably associated with anxiety symptoms mainly during thyrotoxic states 
only; and (e) gonadal hormones, specifically testosterone, may be low in anxiety, while 
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menstrual fluctuations in reports of anxiety severity may implicate other changes as well. 
In addition to pituitary hormones, glucose and glucose regulatory hormones may be affected 
under some circumstances. Glucose (Hall & Brown, 1979) and glucagon and insulin (Curtis, 
1979) concentrations are responsive to stress, and insulin (but not glucagon) increases during 
phobic anxiety (Nesse et al., 1985a). However, insulin concentrations did not change during 
lactate-induced panic (Gorman et  al., 1984b), and hypoglycemia is symptomatically different 
from panic attacks (Lader, 1981; Uhde et al., 1984b; Schweizer et al.,  1986b; Cameron et al., 
1988). 
Melatonin, a product of the pineal gland which is under adrenergic control and which shows 
a large circadian variation, has been studied in panic patients. Mclntyre et al. (1986) and 
Cameron et  al .  (1987) reported reductions in normal nighttime plasma melatonin 
concentrations. Plasma B-endorphin concentrations were elevated during phobic anxiety in a 
single simple phobic patient (Thyer & Matthews, 1986), but not in response to lactate in panic 
patients (Carr et  al., 1986). 
Other circulating substances potentially related to hormonal activity also have been studied. 
Lactic acid was elevated in normal subjects under stress (Hall & Brown, 1979), but not always 
in panic patients compared to normal subjects at rest (Nesse et al., 1984; Liebowitz et al., 1985; 
Carr et al., 1986). Exercise, however, does raise lactate more in people with anxiety than in 
normal subjects (Jones & Mellersh, 1946; Cohen & White, 1950; Holmgren & Strom, 1959). 
Cyclic AMP levels were elevated in both normal and "neurotic" (anxious?) patients in response 
to stress (Moyes & Moyes, 1977; Okada et al., 1983), although levels in panic patients were in 
the normal range (Nesse et al.,  1984). The glucose regulatory and lactic acid abnormalities 
suggest a possible dysfunction of metabolic energy regulation (Cryer, 1984); systemic 
catecholamine abnormalities might be involved in this dysfunction. 
Enzyme activity levels also have been studied. Platelet monoamine oxidase (MAO) activity 
is elevated in some anxious individuals (Davidson et al., 1980; Mathew et al., 1981a; Yu et al., 
1982; Gorman et al., 1985); levels were reduced by relaxation training (Mathew et al., 1981a). 
However, one study reported decreases in MAO in anxious patients (Khan et  al.,  1986). 
Patients with panic attacks had elevated activity of MAO (Gorman et al.,  1985). Dopamine-B- 
hydroxylase was normal in generalized anxiety patients (Mathew et al., 1981b; Friedman et al., 
1984); it was reduced by relaxation (Mathew et  al.,  1981b). Catechol-0-methyl transferase 
(COMT) levels were normal in generalized anxiety patients, and no relaxation effect was 
observed (Mathew et al., 1980a). Low COMT levels were correlated with high levels of trait 
anxiety (Mathew et  al., 1980c), and in another study (Shulman et al.,  1978) patients with severe 
anxiety had higher levels than depressed patients. In that study (Shulman et  al. ,  1978), 
however, agitation in depressed patients predicted high COMT levels in the depressed patients, 
suggesting that agitation rather than anxiety p e r  se might account for the elevations observed in 
anxiety. Acetylcholinesterase was normal in generalized anxiety patients, while 
pseudocholinesterase was elevated; no relaxation effect was observed (Mathew et  al., 1980b). 
Finally, 13-thromboglobulin and platelet factor IV were reported to be elevated in panic patients 
(Sheehan et  a l . ,  1983a), although we did not observe this (unpublished data). Thus, 
monoamine oxidase levels appear to be abnormal; this might be associated with abnormalities 
in systemic catecholamine levels. 
Elevations (Giannini et al., 1983; Davis et al., 1985) as well as decreases (Evans et al., 
1985) of plasma serotonin, and decreased urinary 5-HIAA (Giannini et al.,  1983), have been 
reported in small groups of anxious individuals. Platelet serotonin uptake has been reported to 
be abnormal in panic patients (Norman et al., 1986), but platelet serotonin levels were normal 
(Balon et al., 1987). Finally, plasma HVA, a metabolite of dopamine, was not significantly 
elevated in panic patients (Roy-Byrne et  al. ,  1986a); however, a bimodal distribution was 
observed, with the most anxious patients tending to have higher concentrations. 
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TABLE II. PHYSIOLOGICAL FUNCTIONING IN ANXIETY DISORDERS 
Physiological  Function Status in Anxious  Patients Compared to Normal  Subjects 
Heart Rate Often increased during anxiety of all kinds; may be normal in anxiety 
disorder patients when not acutely anxious 
Probably increased frequency in panic patients 
Present more frequently in BII phobic patients 
Mitral Valve Prolapse 
Diphasic Tachycardia - 
Bradyeardia Response 
Blood Pressure 
Finger Pulse Volume 
Forearm Blood Flow 
Galvanic Skin Response (GSR) 
(measure of sweating) 
Eleetromyographieally (EMG) 





Urination and Defecation 
Finger Tremor 
Probably slightly increased 




Increased (not in all muscle groups) 






A u t o n o m i c  a n d  Card iovascu lar  Changes  
A wide variety of somatic symptoms have been associated with both normal and 
pathological anxiety; many of these reflect changes in the autonomic nervous system (Lader 
and Marks, 1971; Kelly, 1980; Cameron et  al., 1986b). In a large study of "anxiety neurosis" 
(Wheeler et  al. ,  1950), several autonomic symptoms including palpitations, breathlessness, 
chest pain, and paresthesias were experienced by at least 50% of the patients, with palpitations 
being most common of all symptoms reported. Concerning autonomic changes associated with 
anxiety, a number of physiological parameters have been studied, including heart rate and 
blood pressure, galvanic skin response, electromyographic changes, peripheral blood flow, 
respiration, salivation, pupil changes, body temperature, changes in hollow viscus activity 
including changes in urination and defecation, and the startle and orienting responses. Basal 
and stimulated levels of these parameters in both patients and normal subjects, as well as 
differences between patients and normals in habituation of these parameters, have been 
examined. Most studies have reported hyperactivation of these parameters in patients; 
however, both positive and negative results of studies of habitation, reactivity, and 
"spontaneous" variability have been reported. Furthermore, these changes do not necessarily 
correlate with each other or with subjective ratings of anxiety symptoms (Tyrer & Lader, 1976; 
Morrow & Labrum, 1978; Nesse et  al. ,  1985a). Although changes in these variables in 
response to treatment have been reported (Lang et  al., 1970; Lande, 1982), desynchrony of 
these changes during treatment sometimes has been observed (Grey et  al., 1979; Andrasik e t  
al., 1980; Barlow et al., 1980; McLeod et  al., 1986). 
The physiological findings are summarized in Table II. Heart rate was significantly 
elevated in anxious patients in comparison to normal subjects in most studies (Jones & 
Mellersh, 1946; Tan, 1964; Wing, 1964; Kelly & Walter, 1969; Bond et  al., 1974; Freedman e t  
al., 1984; Roth et  al., 1986; Taylor et  al., 1986; Shear et  al., 1987), but not in all (Ackner, 
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1956; Cameron et al., 1987; Mathew et al., 1980c; Mathew & Wilson, 1986). Heart rate was 
significantly increased during both yohimhine-induced (Charney et al., 1987) and situational 
panic attacks (Woods et al., 1987). Anxious patients seem to be excessively aware of their own 
heart beat (Tyrer et al., 1980; Pyke & Greenberg, 1986) and appear to tolerate exercise less 
well than norrnals, including becoming symptomatic during exercise (Cameron & Hudson, 
1986) and having a greater heart rate response to exercise (Crowe et al., 1979). Finally, a high 
resting heart rate may be associated with the later development of anxiety (Phillips et al., 
1987). 
Many of these and subsequent studies to be reviewed involved experimental procedures in 
which immediate situational variables (i.e., abnormal reactivity) might have contributed, at 
least partially, to observed differences. For example, in one study, although heart rate increases 
were associated with panic attacks, heart rates at other times throughout the day did not differ 
from normal subjects (Freedman et al., 1985). However, we found both panic anxiety patients 
who were "anxious" in anticipation of receiving isoproterenol and patients who were not 
anticipating any injection to have significantly and equally increased heart rates compared to 
normal subjects (unpublished data). Furthermore, heart rate increases are not always present 
even during panic attacks (Taylor et al., 1982; 1986; Freedman et al., 1985; Cameron et al., 
1987). Differences in results between studies might represent different subpopulations of 
anxious patients, some who have prominent autonomic systems and some who do not (Hoehn- 
Saric & McLeod, 1985). Although other cardiac abnormalities such as dysrhythmias also have 
been observed in anxious patients (Kannel et al., 1958; Levander-Lindgren, 1962; Shear, 1986; 
Shear et al., 1987; Cameron et al., 1987), similar abnormalities have been observed in healthy 
normal subjects as well (Brodsky et al., 1977, Sobatka et al., 1981). 
Mitral valve prolapse is a specific cardiac abnormality which may be associated with panic 
anxiety (Crowe, 1985; Nesse et al., 1985b; Dager et al., 1986a; 1986b; Gorman et al., 1986b; 
Liberthson et al., 1986) and a variety of autonomic changes (Coghlan et al., 1979; DeCarvalho 
et al., 1979; Gaffney et al., 1979; 1983; Boudoulas et al., 1980; 1983; Clark et al., 1980; 
Pastemac et al., 1982; Puddu et al., 1983). This observation is further support for a possible 
association between anxiety and cardiac and autonomic abnormalities. 
In summary, there is substantial cardiovascular symptomatology, and also evidence for 
cardiac dysfunction, in anxious people; hyperreactivity appears to be important. The meaning 
of the association between panic anxiety and mitral valve prolapse is not yet clear; it might 
reflect manifestations of an underlying autonomic dysfunction, although inconsistencies exist in 
the literature on whether panic patients with and without prolapse differ on measures of 
adrenergic activity (Nesse et al., 1985b; Dager et al., 1987). 
Patients with blood, illness, and injury (BII)("blood-injury" in DSM-III-R) phobia have an 
apparently specific cardiac function abnormality not seen in other anxious patients. The other 
patients usually have acute increases in heart rate in association with acute increases in anxiety, 
followed by returns to pre-anxiety baseline rates. However, BII phobics often show a biphasic 
cardiac response, with the acute tachycardia followed by a significant bradycardia and 
associated fall in blood pressure, often leading to actual vasovagal fainting in these patients; 
this is seen much less often in people with other anxiety disorders (Curtis & Thyer, 1983; Ost 
et al., 1984). Thus, this may be a qualitatively distinct group. 
Vascular as well as cardiac changes have been studied in anxious patients. Blood pressure 
is significantly elevated compared to normal subjects (Innes et al., 1959; Kelly, 1980; Nesse e t  
al., 1985a, Mathew & Wilson, 1986), although the increase is small, not always significant, and 
not always observed (Cameron et al., unpublished data); systolic increases tend to be greater 
than diastolic. Some variability in response to postural change also has been observed (Nesse 
et al., 1984). Blood pressure response to a cold pressor test was the same in panic anxiety 
patients and normal subjects (Grunhaus et al., 1983), but greater in panic patients in response to 
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yohimbine (Charney et  al. ,  1984; 1987a), and less in response to clonidine (Chamey & 
Heninger, 1986a; Nutt, 1986). No significant blood pressure changes have been observed 
during situational panic (Woods et  al., 1987), and neither blood pressure nor heart rate prior to 
infusion is a good predictor of who will have a lactate-induced panic attack (Cowley et al., 
1987; Yeragani et  aL, 1987). 
Finger pulse volume and forearm blood flow are different in anxious patients than in 
normals (Ackner, 1956; Kelly, 1966; 1980; Kelly & Walter, 1969); changes associated with 
acute anxiety also have been observed (Lader & Mathews, 1970). Forearm blood flow 
probably is increased (Jones & MeUersh, 1946; Kelly, 1966; Kelly & Walter, 1969), although 
one study did not find an increase (Harper et al., 1965); pulse volume (Ackner, 1956) and finger 
temperature, a variable which might be expected to correlate positively with pulse volume 
(Freedman et  al. ,  1984), are decreased. These observations are consistent with peripheral 
vasoconstriction associated with dilation of more central vessels, as well as with increased heart 
rate. On the other hand, the reported blood pressure elevations are more consistent with 
systemic vasoconstriction. 
Galvanic skin response (GSR) is a measure of sweating. GSR and related measures have 
demonstrated increased sweating in anxious patients in most (Wing, 1964; Bond et al., 1974; 
Maple et  al., 1982, Quinton, 1983; Roth et  al., 1986) but not all (Ackner, 1956; Freedman e t  
al., 1984) studies; abnormalities in social phobics also have been reported (Dimberg et  al., 
1986). Increases associated with acute anxiety (Lader & Mathews, 1970) and impaired 
habituation to repeated stimuli (Raskin, 1975) have been seen. Increased "spontaneous" 
fluctuations also have been reported (Lader, 1967; Chattapadhyay et  al., 1980). These data are 
in agreement with clinical observations of increased sweating associated with anxiety; 45% of 
patients in one large study reported this symptom (Wheeler et  al., 1950). Sweating associated 
with emotional stress (anxiety?) is usually axillary, palmar, or plantar, this distribution is 
different than sweating which occurs under other circumstances and suggests a qualitative, 
possibly centrally mediated, difference between emotional and other stimuli for sweating 
(Quinton, 1983). 
Electromyographic (EMG) activity is increased in anxious individuals (Sainsbury & 
Gibson, 1954; Goldstein, 1964; Wing, 1964), and increases further in association with acute 
anxiety in some anxious people (Lader & Mathews, 1970). Reactivity studies have produced 
conflicting results (Goldstein, 1964; Wing, 1964). The findings varied among the muscle 
groups tested, and patients with different symptom patterns had different muscle tension 
patterns (Sainsbury & Gibson, 1954). Negative findings concerning differences between 
patients and normals also have been reported (Lader & Wing, 1966). 
Respiratory changes, including the "hyperventilation syndrome," are associated with 
anxiety (Jones & Mellersh, 1946; Coppen & Mezey; 1960, Goldstein, 1964; Lum, 1975; 1976; 
Missri & Alexander, 1978; CompernoUe et  al., 1979; Magarian, 1982; Pincus & Tucker, 1985; 
Bass et  al., 1983; Bass & Gardner, 1985; Clark, 1986). Patients tend to breathe faster and less 
efficiently than normal subjects. This agrees with the frequent clinical complaints of 
respiratory problems such as "breathlessness" in anxious patients (Wheeler et  al., 1950). The 
status of the hyperventilation syndrome vis-a-vis primary anxiety is not clear. The large 
overlap in symptom profiles suggests that many patients in these two groups actually have the 
same disorder;, however, some patients with primary hyperventilation may exist. Furthermore, 
it is not clear whether hyperventilation in primary anxiety patients is a physiological 
abnormality directly associated with the primary anxiety disorder or a secondary 
psychophysiological reaction to anxiety; it may be both - -  different in different patients or in 
the same patient at different times. Panic patients do not have a different ventilatory response 
to CO2 inhalation than do normal subjects (Woods et  al., 1986). In one study (Gorman et al., 
1984a), only 25% of panic patients had panic attacks in response to hyperventilation of room 
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air; nevertheless, the same group of investigators reported evidence that panic patients are 
chronic hyperventilators (Gorman et al., 1986a). 
Physiological functions other than those reviewed above have been studied in anxious 
patients (Lader & Marks, 1971). Data in these other areas are less complete or detailed and 
therefore will be mentioned only briefly. Pupil size is less constricted (Bond et al., 1974), 
orienting responses are inconsistent (Tan, 1964; Lader & Wing, 1966; Bond et al., 1974, Orr & 
Pitman, 1987), salivation is unchanged (Lader & Marks, 1971), the urge to urinate and/or 
defecate is sometimes increased (Wheeler et al., 1950), and finger tremor is increased (Lader, 
1975) in anxious people. 
In summary, there is substantial evidence for autonomic nervous system dysfunction in 
people with anxiety disorders; most consistent has been adrenergic hyperactivity. However, 
like catecholamines (an adrenergic correlate) and other endocrine data, significant 
inconsistencies are apparent. The reasons for these inconsistencies are unknown; they may 
relate to differences in reactivity and habituation, different subpopulations of patients, and/or 
low correlations between physiological changes and reports of subjective symptoms. 
Per iphera l  Recep tor  Status 
Only a few studies have examined peripheral receptor status in patients with anxiety 
disorders. Platelet tx2-adrenoreceptors (maximum number of binding sites - -  Bmax) are 
decreased in patients with panic attacks compared to both normal subjects and depressives 
when yohimbine is the assay ligand; when clonidine is used as the ligand, both normals and 
patients with panic have fewer tx2-receptors than depressives, while panic patients may or may 
not be different than normals (Cameron e t  a l . ,  1984; unpublished data). Binding of 
dihydroergocriptine, a nonspecific tx-adrenoreceptor ligand, was reported to be increased in 
panic patients (Roy-Byme & Uhde, 1985), and another group of investigators did not replicate 
the decrease in yohimbine binding (Nutt & Fraser, 1987); the reason for this discrepancy is not 
known. 
Normal peripheral adrenergic receptor function in panic patients is suggested by identical 
blood pressure and prolactin responses to a cold-pressor test in controls and patients (Grunhaus 
et al., 1983). However, 6-receptor responsiveness was decreased in patients with panic attacks 
when assessed by heart rate responses to graded doses of intravenous isoproterenol (Nesse e t  
al., 1984) and isoproterenol-stimulated cyclic AMP from lymphocytes (Lima & Turner, 1983). 
Receptor down-regulation is consistent with the elevated plasma and urinary catecholarnine 
concentrations often reported in panic disorder patients (Ballenger et al., 1984; Cameron et al., 
1984; Nesse et  al., 1984; 1985a). Generalized anxiety patients have trends toward decreases in 
clonidine binding and yohimbine binding in comparison to normals (Cameron et  al. ,  
unpublished data). 
Imipramine binding to platelets, a putative measure of the serotonin uptake site, appears to 
be normal (Davis et al., 1985; Roy-Byme & Uhde, 1985; Nutt & Fraser, 1987; Schneider et al., 
1987; Uhde et al., 1987). Normal opiate receptor function is suggested by studies in which 
panic patients had responses to naloxone that were minimal and identical to those of control 
subjects (Hoehn-Saric & Masek, 1981; Liebowitz et  al., 1984). However, there may be an 
abnormality in people with obsessive-impulsive disorder (Insel & Pickar, 1983). These data 
may be more relevant for central than peripheral receptor status; the relationship between 
peripheral and central receptor status is not always clear, and the relevance of peripheral 
receptors for the pathophysiology of a centrally mediated state such as anxiety must be 
considered. 
Direct assay of benzodiazepine receptors or benzodiazepine receptor ligands in anxious 
patients is a promising strategy, although relevant peripheral receptor sources may not be 
readily available. Rats selectively bred for "emotionality" (anxiety?) have fewer numbers of 
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brain benzodiazepine receptors than normal rats (Robertson, 1979), and [11C]-R0-15-1788, a 
positron-emitting benzodiazepine receptor antagonist, was specifically bound to brain (cerebral 
and cerebellar cortices and basal nuclei) receptors in monkeys and humans (Persson et al., 
1985). 
DISCUSSION 
The most consistent finding of the research reviewed above is the association of anxiety 
with activation of the adrenergic limb of the autonomic nervous system, as supported by 
(a) endocrine findings (elevated catecholamines and, possibly, monoamine oxidase 
abnormalities, glucose metabolic and lactate abnormalities, and the.similarity between anxious 
and thyrotoxic symptoms); (b) physiological findings (heart rate, blood pressure, galvanic skin 
response, and respiratory abnormalities, as well as the association of panic anxiety with mitral 
valve prolapse); and (c) adrenergic receptor abnormalities. Nevertheless, adrenergic activation 
has not always been observed, and adrenergic symptoms (e.g., heart rate increase) have not 
always been strongly correlated with associated physiological changes. Parasympathetic 
symptoms and physiological abnormalities occurred less frequently. This pattern is similar to 
that seen during stress in normal individuals. 
Other potential psychobiological changes also have been studied, mainly in endocrine 
systems associated with hypothalamic-pituitary regulation. Abnormal activity in several of 
these systems has been observed, but results are often mixed or too preliminary to allow 
specific conclusions. One exception is the normal rate of DST abnormalities in people with 
panic attacks. 
As noted above, a major justification for studying endocrine and physiological changes is 
that these changes might permit inferences about associated changes in the central nervous 
system. Might the changes thus far observed allow any such inferences? Since peripheral 
adrenergic changes are the most consistent abnormalities reported, it seems very likely that 
dysfunction of central control of the peripheral adrenergic system is involved in the 
pathophysiology of anxiety disorders. 
Electrical stimulation of the locus cemleus in monkeys causes a reaction that seems similar 
to fear (anxiety?) (Redmond, 1979). The locus ceruleus, which is located adjacent to the 
aqueduct in the dorsal pons and has many efferents including some to the amygdala, cingulate, 
and hippocampus, is the source of more than 50% of all the norepinephrine irt the brain, and 
most of the cell bodies of the remaining noradrenaline neurons are close by (Redmond, 1979, 
Ziegler & Lake, 1984). The cortex (especially prefrontal and cingulate), the limbic system 
(especially the amygdala), and the hypothalamus all have been implicated in the central control 
of autonomic responses to stress or anxiety (Brooks et al., 1979; Galosy et al., 1981; Mancia & 
Zanchetti, 1981; Brezinoff & Guiliano, 1982; Randall & Hasson, 1982; Anderson, 1984; Herd, 
1984; Randall, 1984; Smith & DeVito, 1984; Verrier & Lown, 1984). Furthermore, central and 
peripheral autonomic activity are associated (Maas & Leckman, 1983; Svensson, 1987). 
Challenge tests with yohimbine, a centrally active adrenergic agent, produce anxiety in 
susceptible individuals (Chamey et al., 1983; 1984; 1987a). Thus, there is support for the 
involvement of central noradrenergic pathways in the genesis of anxiety, and also for the 
involvement of these pathways in control of the peripheral autonomic reactions. 
However, treatment with adrenergically active drugs has produced at best limited support 
for the involvement of central adrenergic mechanisms in anxiety. B-adrenergic antagonists 
such as propranolol seem to be useful mainly for the peripheral adrenergic symptoms of anxiety 
(Cole, 1984; Noyes, 1985), and rapid tolerance develops to the anxiolytic effects of clonidine, 
an o~-adrenoceptor agonist (Hoehn-Saric et al., 1981; Liebowitz et al., 1981). And, buspirone, 
a new anxiolytic drug for generalized anxiety (and panic?) stimulates locus ceruleus firing and 
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(Sanghera & German, 1983; Sanghera et al., 1983). Finally, although peripheral adrenergic ct 2 
13-adrenoreceptors are abnormal in anxious patients, this abnormality may only reflect changes 
in peripheral status and not necessarily central changes. Thus, the evidence for the involvement 
of central noradrenergic systems in anxiety disorders should be considered tentative at this 
time. The potential involvement of other central nervous system pathways which are involved 
in the production of anxiety, including the peripheral adrenergic symptoms, should be further 
explored. 
Patterns of hypothalamic-pituitary hormonal change might permit inferences about 
neurotransmitters involved in anxiety in this brain region (Checkley, 1980; Elias et al., 1982; 
Frohmann & Berelowitz, 1984; Reichlin, 1985; Tuomisto & Mannist6, 1985), but the results 
are not yet extensive or consistent enough to allow specific inferences. However, the results of 
one study (Cameron et al., 1987) have suggested that GABA might be involved. This 
observation would be consistent with research relating GABA, the benzodiazepines, and 
anxiety. 
Benzodiazepines, which are effective anxiolytic agents (Rickels, 1981), appear to function 
through a GABA "macromolecular receptor complex" (Paul et al., 1981; Paul & Skolnick, 
1984); B-carbolines, GABA "inverse agonists," are potent inducers of anxiety in humans 
(Dorow et al., 1983); and caffeine, which also produces anxiety in susceptible individuals 
(Uhde et al., 1984a, Chamey et al., 1985; Lee et al., 1985), may interact with the GABA 
receptor either directly or through adenosine receptors (Snyder & Sklar, 1984; Marangos & 
Boulenger, 1985). However, the pharmacology of buspirone is not fully consistent with the 
assumed mechanisms of action of GABA and the benzodiazepines on anxiety (Eison & 
Temple, 1986). Other neurotransmitters have also been implicated, especially serotonin and 
possibly dopamine (Braestrap, 1982; Hoehn-Saric, 1982; Judd et al., 1985; Eison & Temple, 
1986), however, their details are less well understood. 
As described above, even though some conclusions seemed to be justified, many of the 
observations made in the research reviewed were either inconclusive, too preliminary for firm 
acceptance, or contradicted by other observations. As future research seeks to clarify these 
ambiguities, several sources of potential variability in outcome should be considered: 
(a) individual subject differences (including demographics, age, sex, etc.), and differences 
between diagnostic groups within the overall designation of "anxiety disorder"; (b) reactivity 
and habituation factors, which might differ between anxious individuals and normal subjects 
(e.g., the difference between resting and non-resting state); (c) potential variance between 
physiological changes and patient reports of subjective symptomatology; (d) lack of correlation 
among the various physiological/hormonal changes, including the desynchrony of changes 
sometimes observed during treatment; (e) the difference between observations in the periphery 
and the central nervous system (e.g., what correlations can be expected between peripheral 
receptors or peripheral autonomic functioning and central neurotransmitter function); (f) to 
what extent results of studies which used pharmacological challenges are due to anxiety 
induction vs. direct pharmacologic effects, as well as the issue of whether differences in such 
studies between anxious individuals and normals are qualitative vs. quantitative; and 
(g) whether the pathophysiological changes observed are directly related to etiology vs. being 
only indirectly involved (e.g., as "upstream" or "downstream" effects). Two other issues of 
importance are: (a) what knowledge about the pathophysiology of anxiety can be obtained 
from observations about effective treatment methods, including the observation that non- 
pharmacologic methods can modify the physiological anxiety response; and (b) as noted above, 
what the psychobiological relationship is between anxiety disorders and stress in normal 
subjects, and correlatively, is the stress response different in anxious individuals? In other 
words, are the psychobiology of stress in normal persons and the psychobiology of anxiety 
reactions in patients with anxiety disorders really different? One hypothesis which seems to be 
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consistent with many of  the observed data is that the "switch" or "trigger" which sets off an 
anxiety reaction is different, at least quantitatively and probably also qualitatively, in people 
with anxiety disorders vs. stress ("anxiety") in normals, but that once a reaction occurs, the 
psychophys io log ica l  symptoms  are fairly similar (even though the pattern o f  hormonal  
response ,  e spec i a l l y  ep inephr ine ,  m a y  be di f ferent) .  A sys t ema t i c  inqui ry  into the 
psychobiology of  anxiety disorders will need to attend to all these issues. 
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